STAT proteins - Key regulators of anti-viral responses, inflammation, and tumorigenesis in the liver

Journal of Hepatology

Volumn 57, Issue 2, 2012, Pages 430-441

  Gao, Bin ^a   Wang, Hua ^a   Lafdil, Fouad ^b,c   Feng, Dechun ^a  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b INSERM U955   (France)

^c FACULTÉ DE MÉDECINE   (France)

Author keywords

HCV; Interferon; Liver injury; Liver regeneration; Liver tumor

Indexed keywords

ALPHA INTERFERON; INTERLEUKIN 22; PEGINTERFERON ALPHA; RIBAVIRIN; SORAFENIB; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT6 PROTEIN;

ANTIVIRAL ACTIVITY; BONE MARROW CELL; CANCER INHIBITION; DRUG POTENCY; HEPATITIS C; HOST RESISTANCE; HUMAN; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL; LIVER INJURY; LIVER PROTECTION; LIVER REGENERATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; VIRUS HEPATITIS;

ANIMALS; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS; LIVER REGENERATION; STAT TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84863989928     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.01.029     Document Type: Review

References (134)

1. J.E. Darnell Jr., I.M. Kerr, and G.R. Stark Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins Science 264 1994 1415 1421
2. C. Schindler Cytokines and JAK-STAT signaling Exp Cell Res 253 1999 7 14
3. B. Gao Cytokines, STATs and liver disease Cell Mol Immunol 2 2005 92 100
4. S. Ruff-Jamison, K. Chen, and S. Cohen Induction by EGF and interferon-gamma of tyrosine phosphorylated DNA binding proteins in mouse liver nuclei Science 261 1993 1733 1736
5. K. Machida, H. Tsukamoto, J.C. Liu, Y.P. Han, S. Govindarajan, and M.M. Lai C-Jun mediates hepatitis C virus hepatocarcinogenesis through signal transducer and activator of transcription 3 and nitric oxide-dependent impairment of oxidative DNA repair Hepatology 52 2010 480 492
6. S. Wormald, and D.J. Hilton Inhibitors of cytokine signal transduction J Biol Chem 279 2004 821 824
7. W.S. Alexander, and D.J. Hilton The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response Annu Rev Immunol 22 2004 503 529
8. F. Hong, B. Jaruga, W.H. Kim, S. Radaeva, O.N. El-Assal, and Z. Tian Opposing roles of STAT1 and STAT3 in T cell-mediated hepatitis: regulation by SOCS J Clin Invest 110 2002 1503 1513
9. B.A. Croker, D.L. Krebs, J.G. Zhang, S. Wormald, T.A. Willson, and E.G. Stanley SOCS3 negatively regulates IL-6 signaling in vivo Nat Immunol 4 2003 540 545
10. B. Rehermann Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence J Clin Invest 119 2009 1745 1754
11. G. Ahlenstiel, R.H. Titerence, C. Koh, B. Edlich, J.J. Feld, and Y. Rotman Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner Gastroenterology 138 2010 325 335 e321-e322
12. K. Cheent, and S.I. Khakoo Natural killer cells and hepatitis C: action and reaction Gut 60 2011 268 278
13. L. Golden-Mason, A.L. Cox, J.A. Randall, L. Cheng, and H.R. Rosen Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro Hepatology 52 2010 1581 1589
14. B. Amadei, S. Urbani, A. Cazaly, P. Fisicaro, A. Zerbini, and P. Ahmed Activation of natural killer cells during acute infection with hepatitis C virus Gastroenterology 138 2010 1536 1545
15. K.A. Stegmann, N.K. Bjorkstrom, H. Veber, S. Ciesek, P. Riese, and J. Wiegand Interferon-alpha-induced TRAIL on natural killer cells is associated with control of hepatitis C virus infection Gastroenterology 138 2010 1885 1897
16. G. Ahlenstiel, B. Edlich, L.J. Hogdal, Y. Rotman, M. Noureddin, and J.J. Feld Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C Gastroenterology 141 2011 1231 1239 e1232
17. S.H. Wang, C.X. Huang, L. Ye, X. Wang, L. Song, and Y.J. Wang Natural killer cells suppress full cycle HCV infection of human hepatocytes J Viral Hepat 15 2008 855 864
18. T. Miyagi, T. Takehara, K. Nishio, S. Shimizu, K. Kohga, and W. Li Altered interferon-alpha-signaling in natural killer cells from patients with chronic hepatitis C virus infection J Hepatol 53 2010 424 430
19. B. Edlich, G. Ahlenstiel, A.Z. Azpiroz, J. Stoltzfus, M. Noureddin, and E. Serti Early changes in interferon signaling define natural killer cell response and refractoriness to interferon-based therapy of hepatitis C Hepatology 55 2012 39 48
20. R.P. Donnelly, and S.V. Kotenko Interferon-lambda: a new addition to an old family J Interferon Cytokine Res 30 2010 555 564
21. J. Diegelmann, F. Beigel, K. Zitzmann, A. Kaul, B. Goke, and C.J. Auernhammer Comparative analysis of the lambda-interferons IL-28A and IL-29 regarding their transcriptome and their antiviral properties against hepatitis C virus PLoS One 5 2010 e15200
22. T. Marcello, A. Grakoui, G. Barba-Spaeth, E.S. Machlin, S.V. Kotenko, and M.R. MacDonald Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics Gastroenterology 131 2006 1887 1898
23. R.P. Donnelly, H. Dickensheets, and T.R. O'Brien Interferon-lambda and therapy for chronic hepatitis C virus infection Trends Immunol 32 2011 443 450
24. L. Zhang, N. Jilg, R.X. Shao, W. Lin, D.N. Fusco, and H. Zhao IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway J Hepatol 55 2011 289 298
25. N.E. Pagliaccetti, R. Eduardo, S.H. Kleinstein, X.J. Mu, P. Bandi, and M.D. Robek Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication J Biol Chem 283 2008 30079 30089
26. M.D. Robek, B.S. Boyd, and F.V. Chisari Lambda interferon inhibits hepatitis B and C virus replication J Virol 79 2005 3851 3854
27. A.J. Muir, M.L. Shiffman, A. Zaman, B. Yoffe, A. de la Torre, and S. Flamm Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection Hepatology 52 2010 822 832
28. E.L. Ramos Preclinical and clinical development of pegylated interferon-lambda 1 in chronic hepatitis C J Interferon Cytokine Res 30 2010 591 595
29. N.H. Afdhal, J.G. McHutchison, S. Zeuzem, A. Mangia, J.M. Pawlotsky, and J.S. Murray Hepatitis C pharmacogenetics: state of the art in 2010 Hepatology 53 2011 336 345
30. A. Balagopal, D.L. Thomas, and C.L. Thio IL28B and the control of hepatitis C virus infection Gastroenterology 139 2010 1865 1876
31. C.M. Lange, and S. Zeuzem IL28B single nucleotide polymorphisms in the treatment of hepatitis C J Hepatol 55 2011 692 701
32. C.M. Lange, D. Moradpour, A. Doehring, H.A. Lehr, B. Mullhaupt, and S. Bibert Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection J Hepatol 55 2011 322 327
33. T. Fukuhara, A. Taketomi, T. Motomura, S. Okano, A. Ninomiya, and T. Abe Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C Gastroenterology 139 2010 1577 1585
34. M.R. Charlton, A. Thompson, B.J. Veldt, K. Watt, H. Tillmann, and J.J. Poterucha Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection Hepatology 53 2011 317 324
35. B. Langhans, B. Kupfer, I. Braunschweiger, S. Arndt, W. Schulte, and H.D. Nischalke Interferon-lambda serum levels in hepatitis C J Hepatol 54 2011 859 865
36. H. Abe, C.N. Hayes, H. Ochi, T. Maekawa, M. Tsuge, and D. Miki IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy J Hepatol 54 2011 1094 1101
37. T.J. Urban, A.J. Thompson, S.S. Bradrick, J. Fellay, D. Schuppan, and K.D. Cronin IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C Hepatology 52 2010 1888 1896
38. Z. Makowska, F.H. Duong, G. Trincucci, D.F. Tough, and M.H. Heim Interferon-beta and interferon-lambda signaling is not affected by interferon-induced refractoriness to interferon-alpha in vivo Hepatology 53 2011 1154 1163
39. S. Radaeva, B. Jaruga, F. Hong, W.H. Kim, S. Fan, and H. Cai Interferon-alpha activates multiple STAT signals and down-regulates c- Met in primary human hepatocytes Gastroenterology 122 2002 1020 1034
40. M. Mair, L. Blaas, C.H. Osterreicher, E. Casanova, and R. Eferl JAK-STAT signaling in hepatic fibrosis Front Biosci 17 2011 2794 2811
41. T. Torisu, M. Nakaya, S. Watanabe, M. Hashimoto, H. Yoshida, and T. Chinen Suppressor of cytokine signaling 1 protects mice against concanavalin A-induced hepatitis by inhibiting apoptosis Hepatology 47 2008 1644 1654
42. F. Lafdil, H. Wang, O. Park, W. Zhang, Y. Moritoki, and S. Yin Myeloid STAT3 inhibits T cell-mediated hepatitis by regulating T helper 1 cytokine and interleukin-17 production Gastroenterology 137 2009 2125 2135 e2121-e2122
43. C. Klein, T. Wustefeld, U. Assmus, T. Roskams, S. Rose-John, and M. Muller The IL-6-gp130-STAT3 pathway in hepatocytes triggers liver protection in T cell-mediated liver injury J Clin Invest 115 2005 860 869
44. J. Siebler, S. Wirtz, S. Klein, M. Protschka, M. Blessing, and P.R. Galle A key pathogenic role for the STAT1/T-bet signaling pathway in T-cell-mediated liver inflammation Hepatology 38 2003 1573 1580
45. L.A. Zenewicz, G.D. Yancopoulos, D.M. Valenzuela, A.J. Murphy, M. Karow, and R.A. Flavell Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation Immunity 27 2007 647 659
46. H. Ogata, T. Kobayashi, T. Chinen, H. Takaki, T. Sanada, and Y. Minoda Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis Gastroenterology 131 2006 179 193
47. O. Park, H. Wang, H. Weng, L. Feigenbaum, H. Li, and S. Yin In vivo consequences of liver-specific interleukin-22 expression in mice. Implications for human liver disease progression Hepatology 54 2011 252 261
48. J. Siebler, S. Wirtz, C. Frenzel, M. Schuchmann, A.W. Lohse, and P.R. Galle Cutting edge: a key pathogenic role of IL-27 in T cell-mediated hepatitis J Immunol 180 2008 30 33
49. W.H. Kim, F. Hong, S. Radaeva, B. Jaruga, S. Fan, and B. Gao STAT1 plays an essential role in LPS/D-galactosamine-induced liver apoptosis and injury Am J Physiol Gastrointest Liver Physiol 285 2003 G761 G768
50. N. Horiguchi, F. Lafdil, A.M. Miller, O. Park, H. Wang, and M. Rajesh Dissociation between liver inflammation and hepatocellular damage induced by carbon tetrachloride in myeloid cell-specific signal transducer and activator of transcription 3 gene knockout mice Hepatology 51 2010 1724 1734
51. M. Mair, G. Zollner, D. Schneller, M. Musteanu, P. Fickert, and J. Gumhold Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis Gastroenterology 138 2010 2499 2508
52. D.C. Kroy, N. Beraza, D.F. Tschaharganeh, L.E. Sander, S. Erschfeld, and A. Giebeler Lack of interleukin-6/glycoprotein 130/signal transducers and activators of transcription-3 signaling in hepatocytes predisposes to liver steatosis and injury in mice Hepatology 51 2010 463 473
53. N. Horiguchi, L. Wang, P. Mukhopadhyay, O. Park, W.I. Jeong, and F. Lafdil Cell type-dependent pro- and anti-inflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury Gastroenterology 134 2008 1148 1158
54. S.H. Ki, O. Park, M. Zheng, O. Morales-Ibanez, J.K. Kolls, and R. Bataller Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3 Hepatology 52 2010 1291 1300
55. S. Haga, K. Terui, H.Q. Zhang, S. Enosawa, W. Ogawa, and H. Inoue Stat3 protects against Fas-induced liver injury by redox-dependent and -independent mechanisms J Clin Invest 112 2003 989 998
56. R. Taub Hepatoprotection via the IL-6/Stat3 pathway J Clin Invest 112 2003 978 980
57. H. Wang, F. Lafdil, X. Kong, and B. Gao Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target Int J Biol Sci 7 2011 536 550
58. R. Sun, O. Park, N. Horiguchi, S. Kulkarni, W.I. Jeong, and H.Y. Sun STAT1 contributes to dsRNA inhibition of liver regeneration after partial hepatectomy in mice Hepatology 44 2006 955 966
59. B. Jaruga, F. Hong, W.H. Kim, and B. Gao IFN-{gamma}/STAT1 acts as a proinflammatory signal in T cell-mediated hepatitis via induction of multiple chemokines and adhesion molecules: a critical role of IRF-1 Am J Physiol Gastrointest Liver Physiol 287 2004 G1044 G1052
60. H. Wang, O. Park, F. Lafdil, K. Shen, N. Horiguchi, and S. Yin Interplay of hepatic and myeloid signal transducer and activator of transcription 3 in facilitating liver regeneration via tempering innate immunity Hepatology 51 2010 1354 1362
61. W. Li, X. Liang, C. Kellendonk, V. Poli, and R. Taub STAT3 contributes to the mitogenic response of hepatocytes during liver regeneration J Biol Chem 277 2002 28411 28417
62. G.K. Michalopoulos Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas Am J Pathol 176 2010 2 13
63. N. Fausto, J.S. Campbell, and K.J. Riehle Liver regeneration Hepatology 43 2006 S45 S53
64. D.E. Cressman, L.E. Greenbaum, R.A. DeAngelis, G. Ciliberto, E.E. Furth, and V. Poli Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice Science 274 1996 1379 1383 New York, NY
65. T. Sakamoto, Z. Liu, N. Murase, T. Ezure, S. Yokomuro, and V. Poli Mitosis and apoptosis in the liver of interleukin-6-deficient mice after partial hepatectomy Hepatology 29 1999 403 411
66. A. Blindenbacher, X. Wang, I. Langer, R. Savino, L. Terracciano, and M.H. Heim Interleukin 6 is important for survival after partial hepatectomy in mice Hepatology 38 2003 674 682 Baltimore, MD
67. R. Sun, B. Jaruga, S. Kulkarni, H. Sun, and B. Gao IL-6 modulates hepatocyte proliferation via induction of HGF/p21cip1: regulation by SOCS3 Biochem Biophys Res Commun 338 2005 1943 1949
68. T. Wuestefeld, C. Klein, K.L. Streetz, U. Betz, J. Lauber, and J. Buer Interleukin-6/glycoprotein 130-dependent pathways are protective during liver regeneration J Biol Chem 278 2003 11281 11288
69. U. Dierssen, N. Beraza, H.H. Lutz, C. Liedtke, M. Ernst, and H.E. Wasmuth Molecular dissection of gp130-dependent pathways in hepatocytes during liver regeneration J Biol Chem 283 2008 9886 9895
70. A. Moh, Y. Iwamoto, G.X. Chai, S.S. Zhang, A. Kano, and D.D. Yang Role of STAT3 in liver regeneration: survival, DNA synthesis, inflammatory reaction and liver mass recovery Lab Invest 87 2007 1018 1028
71. K.J. Riehle, J.S. Campbell, R.S. McMahan, M.M. Johnson, R.P. Beyer, and T.K. Bammler Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3 J Exp Med 205 2008 91 103
72. R. Sun, and B. Gao Negative regulation of liver regeneration by innate immunity (natural killer cells/interferon-gamma) Gastroenterology 127 2004 1525 1539
73. S. Radaeva, B. Jaruga, W.H. Kim, T. Heller, T.J. Liang, and B. Gao Interferon-gamma inhibits interferon-alpha signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C Biochem J 379 2004 199 208
74. R. Sakamori, T. Takehara, C. Ohnishi, T. Tatsumi, K. Ohkawa, and K. Takeda Signal transducer and activator of transcription 3 signaling within hepatocytes attenuates systemic inflammatory response and lethality in septic mice Hepatology 46 2007 1564 1573
75. H. Wang, F. Lafdil, L. Wang, O. Park, S. Yin, and J. Niu Hepatoprotective versus oncogenic functions of STAT3 in liver tumorigenesis Am J Pathol 179 2011 714 724
76. P.J. Murray Understanding and exploiting the endogenous interleukin-10/STAT3-mediated anti-inflammatory response Curr Opin Pharmacol 6 2006 379 386
77. K. Numata, M. Kubo, H. Watanabe, K. Takagi, H. Mizuta, and S. Okada Overexpression of suppressor of cytokine signaling-3 in T cells exacerbates acetaminophen-induced hepatotoxicity J Immunol 178 2007 3777 3785
78. M.H. Kaplan STAT4: a critical regulator of inflammation in vivo Immunol Res 31 2005 231 242
79. M.C. Rodriguez-Galan, D. Reynolds, S.G. Correa, P. Iribarren, M. Watanabe, and H.A. Young Coexpression of IL-18 strongly attenuates IL-12-induced systemic toxicity through a rapid induction of IL-10 without affecting its antitumor capacity J Immunol 183 2009 740 748
80. K. Yoshida, G.X. Yang, W. Zhang, M. Tsuda, K. Tsuneyama, and Y. Moritoki Deletion of interleukin-12p40 suppresses autoimmune cholangitis in dominant negative transforming growth factor beta receptor type II mice Hepatology 50 2009 1494 1500
81. R. Zhu, S. Diem, L.M. Araujo, A. Aumeunier, J. Denizeau, and E. Philadelphe The Pro-Th1 cytokine IL-12 enhances IL-4 production by invariant NKT cells: relevance for T cell-mediated hepatitis J Immunol 178 2007 5435 5442
82. C.J. Chang, Y.H. Chen, K.W. Huang, H.W. Cheng, S.F. Chan, and K.F. Tai Combined GM-CSF and IL-12 gene therapy synergistically suppresses the growth of orthotopic liver tumors Hepatology 45 2007 746 754
83. N. Harada, M. Shimada, S. Okano, T. Suehiro, Y. Soejima, and Y. Tomita IL-12 gene therapy is an effective therapeutic strategy for hepatocellular carcinoma in immunosuppressed mice J Immunol 173 2004 6635 6644
84. J.J. Subleski, V.L. Hall, T.C. Back, J.R. Ortaldo, and R.H. Wiltrout Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver Cancer Res 66 2006 11005 11012
85. X.D. Shen, B. Ke, Y. Zhai, F. Gao, D. Anselmo, and C.R. Lassman Stat4 and Stat6 signaling in hepatic ischemia/reperfusion injury in mice. HO-1 dependence of Stat4 disruption-mediated cytoprotection Hepatology 37 2003 296 303
86. A. Kato, A. Graul-Layman, M.J. Edwards, and A.B. Lentsch Promotion of hepatic ischemia/reperfusion injury by IL-12 is independent of STAT4 Transplantation 73 2002 1142 1145
87. B. Jaruga, F. Hong, R. Sun, S. Radaeva, and B. Gao Crucial role of IL-4/STAT6 in T cell-mediated hepatitis: up-regulating eotaxins and IL-5 and recruiting leukocytes J Immunol 171 2003 3233 3244
88. S. Higuchi, M. Kobayashi, Y. Yoshikawa, K. Tsuneyama, T. Fukami, and M. Nakajima IL-4 mediates dicloxacillin-induced liver injury in mice Toxicol Lett 200 2011 139 145
89. D.B. Njoku, Z. Li, N.D. Washington, J.L. Mellerson, M.V. Talor, and R. Sharma Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury Eur J Immunol 39 2009 1652 1663
90. D.B. Douglas, D.P. Beiting, J.P. Loftus, J.A. Appleton, and S.K. Bliss Combinatorial effects of interleukin 10 and interleukin 4 determine the progression of hepatic inflammation following murine enteric parasitic infection Hepatology 51 2010 2162 2171
91. P.B.M. Ryan, M.C. Korrapati, W.R. Proctor, R.V. Vasquez, S.B. Yee, and T.D. Quinn Endogenous interleukin-4 regulates glutathione synthesis following acetaminophen-induced liver injury in mice Chem Res Toxicol 25 2012 83 93
92. A. Kato, H. Yoshidome, M.J. Edwards, and A.B. Lentsch Reduced hepatic ischemia/reperfusion injury by IL-4: potential anti-inflammatory role of STAT6 Inflamm Res 49 2000 275 279
93. A. Kato, T. Okaya, and A.B. Lentsch Endogenous IL-13 protects hepatocytes and vascular endothelial cells during ischemia/reperfusion injury Hepatology 37 2003 304 312
94. H. Yoshidome, A. Kato, M. Miyazaki, M.J. Edwards, and A.B. Lentsch IL-13 activates STAT6 and inhibits liver injury induced by ischemia/reperfusion Am J Pathol 155 1999 1059 1064
95. B. Ke, X.D. Shen, F. Gao, R.W. Busuttil, and J.W. Kupiec-Weglinski Interleukin 13 gene transfer in liver ischemia and reperfusion injury: role of Stat6 and TLR4 pathways in cytoprotection Hum Gene Ther 15 2004 691 698
96. Z. Cao, Y. Yuan, G. Jeyabalan, Q. Du, A. Tsung, and D.A. Geller Preactivation of NKT cells with alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor Am J Physiol Gastrointest Liver Physiol 297 2009 G249 G258
97. L. Adámková, and J. Kovarík Transcription protein STAT1: biology and relation to cancer Folia Biol (Praha) 53 2007 1 6
98. D.H. Kaplan, V. Shankaran, A.S. Dighe, E. Stockert, M. Aguet, and L.J. Old Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice Proc Natl Acad Sci U S A 95 1998 7556 7561
99. C.K. Lee, E. Smith, R. Gimeno, R. Gertner, and D.E. Levy STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-gamma J Immunol 164 2000 1286 1292
100. Z.Z. Zhu, J.Z. Di, W.Y. Gu, W.M. Cong, A. Gawron, and Y. Wang Association of genetic polymorphisms in STAT1 gene with increased risk of hepatocellular carcinoma Oncology 78 2010 382 388
101. H. Nagano Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon Oncology 78 2010 142 147
102. E.B. Haura, J. Turkson, and R. Jove Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer Nat Clin Pract Oncol 2 2005 315 324
103. H. Yu, and R. Jove The STATs of cancer - new molecular targets come of age Nat Rev Cancer 4 2004 97 105
104. G. He, and M. Karin NF-kappaB and STAT3 - key players in liver inflammation and cancer Cell Res 21 2011 159 168
105. L. Lin, R. Amin, G.I. Gallicano, E. Glasgow, W. Jogunoori, and J.M. Jessup The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling Oncogene 28 2009 961 972
106. D.F. Calvisi, S. Ladu, A. Gorden, M. Farina, E.A. Conner, and J.S. Lee Ubiquitous activation of Ras and Jak/Stat pathways in human HCC Gastroenterology 130 2006 1117 1128
107. R.T.Z. Jiang, L. Deng, Y. Chen, Y. Xia, Y. Gao, and X. Wang Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3 Hepatology 54 2011 900 909
108. H. Yoshikawa, K. Matsubara, G.S. Qian, P. Jackson, J.D. Groopman, and J.E. Manning SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity Nat Genet 28 2001 29 35
109. Y. Niwa, H. Kanda, Y. Shikauchi, A. Saiura, K. Matsubara, and T. Kitagawa Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma Oncogene 24 2005 6406 6417
110. J.F. Zhang, M.L. He, W.M. Fu, H. Wang, L.Z. Chen, and X. Zhu Primate-specific miRNA-637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting stat3 signaling Hepatology 54 2011 2137 2148
111. D.M. Avella, G. Li, T.D. Schell, D. Liu, and S. Shao-Min Zhang Regression of established hepatocellular carcinoma is induced by chemo-immunotherapy in an orthotopic murine model Hepatology 55 2012 141 152
112. C. Wang, W. Yang, H.X. Yan, T. Luo, J. Zhang, and L. Tang HBx induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4- dihydrocollidine (DDC) treated HBx transgenic mice Hepatology 55 2012 108 120
113. W.E. Naugler, T. Sakurai, S. Kim, S. Maeda, K. Kim, and A.M. Elsharkawy Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production Science 317 2007 121 124
114. E.J. Park, J.H. Lee, G.Y. Yu, G. He, S.R. Ali, and R.G. Holzer Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression Cell 140 2010 197 208
115. E.A. Bard-Chapeau, S. Li, J. Ding, S.S. Zhang, H.H. Zhu, and F. Princen Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis Cancer Cell 19 2011 629 639
116. G. He, G.Y. Yu, V. Temkin, H. Ogata, C. Kuntzen, and T. Sakurai Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation Cancer Cell 17 2010 286 297
117. D. Schneller, G. Machat, A. Sousek, V. Proell, F. van Zijl, and G. Zulehner P19(ARF)/p14(ARF) controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma Hepatology 54 2011 164 172
118. D.F. Calvisi Dr. Jekyll, Mr. Hyde: a paradoxical oncogenic and tumor suppressive role of signal transducer and activator of transcription 3 in liver cancer Hepatology 54 2011 9 12
119. G. Ferbeyre, and R. Moriggl The role of Stat5 transcription factors as tumor suppressors or oncogenes Biochim Biophys Acta 1815 2011 104 114
120. A. Hosui, A. Kimura, D. Yamaji, B.M. Zhu, R. Na, and L. Hennighausen Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation J Exp Med 206 2009 819 831
121. K.M. Mueller, J.W. Kornfeld, K. Friedbichler, L. Blaas, G. Egger, and H. Esterbauer Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice Hepatology 54 2011 1398 1409
122. K.T.M. Friedbichler, K.M. Mueller, M. Schlederer, J.W. Kornfeld, L.M. Terracciano, and A.V. Kozlov Growth hormone-induced STAT5 signaling causes gigantism, inflammation and premature death but protects mice from aggressive liver cancer Hepatology 55 2012 941 952
123. J.H. Yu, B.M. Zhu, M. Wickre, G. Riedlinger, W. Chen, and A. Hosui The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression Hepatology 52 2010 1808 1818
124. J.J. Feld, A.A. Modi, R. El-Diwany, Y. Rotman, E. Thomas, and G. Ahlenstiel S-adenosyl methionine improves early viral responses and interferon-stimulated gene induction in hepatitis C nonresponders Gastroenterology 140 2011 830 839
125. B.D. Page, D.P. Ball, and P.T. Gunning Signal transducer and activator of transcription 3 inhibitors: a patent review Expert Opin Ther Pat 21 2011 65 83
126. M. Iavarone, G. Cabibbo, F. Piscaglia, C. Zavaglia, A. Grieco, and E. Villa Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy Hepatology 54 2011 2055 2063
127. J.M. Llovet, S. Ricci, V. Mazzaferro, P. Hilgard, E. Gane, and J.F. Blanc Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
128. A. Villanueva, and J.M. Llovet Targeted therapies for hepatocellular carcinoma Gastroenterology 140 2011 1410 1426
129. A.B. Siegel, S.K. Olsen, A. Magun, and R.S. Brown Jr. Sorafenib: where do we go from here? Hepatology 52 2010 360 369
130. B.R. Blechacz, R.L. Smoot, S.F. Bronk, N.W. Werneburg, A.E. Sirica, and G.J. Gores Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2 Hepatology 50 2009 1861 1870
131. W.T. Tai, A.L. Cheng, C.W. Shiau, H.P. Huang, J.W. Huang, and P.J. Chen Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma J Hepatol 55 2011 1041 1048
132. O. Rosmorduc, and C. Desbois-Mouthon Targeting STAT3 in hepatocellular carcinoma: Sorafenib again J Hepatol 55 2011 957 959
133. S. Radaeva, R. Sun, H.N. Pan, F. Hong, and B. Gao Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation Hepatology 39 2004 1332 1342
134. L. Yang, Y. Zhang, L. Wang, F. Fan, L. Zhu, and Z. Li Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22 J Hepatol 53 2010 339 347